CARsgen Therapeutics Holdings Limited (OTC:CRTHF) Short Interest Up 45.9% in May

CARsgen Therapeutics Holdings Limited (OTC:CRTHF) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 610,500 shares, a growth of 45.9% from the May 15th total of 418,500 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

CARsgen Therapeutics Price Performance

Shares of CARsgen Therapeutics stock opened at $0.76 on Wednesday. The firm has a fifty day moving average price of $0.76 and a 200 day moving average price of $0.76. CARsgen Therapeutics has a 1 year low of $0.75 and a 1 year high of $0.95.

CARsgen Therapeutics Company Profile

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).